Prospects of minimally invasive surgery in the treatment of primary open-angle glaucoma

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article examines the prospects of minimally invasive glaucoma surgery in the treatment of primary open-angle glaucoma. The primary focus is on the effectiveness and safety of contemporary minimally invasive glaucoma surgery techniques, such as iStent, MicroShunt, and Hydrus. The authors highlight the significant reduction in intraocular pressure and the decrease in dependence on medication therapy for most patients following these procedures. The article presents results from numerous clinical studies demonstrating the high effectiveness and safety of these methods. The uniqueness of this review lies in the comprehensive analysis of current data and the identification of key advantages of minimally invasive glaucoma surgery compared to traditional glaucoma treatment methods. The article also emphasizes the economic feasibility of minimally invasive glaucoma surgery, which can significantly reduce the burden on healthcare systems in various regions. The authors point out the necessity for further research to evaluate the long-term effectiveness and safety of these technologies, as well as to determine optimal management strategies for primary open-angle glaucoma in different population subgroups. Detailed meta-analyses and multicenter studies could contribute to better understanding of the mechanisms of action and potential limitations of these technologies, providing a basis for personalized approach to glaucoma treatment.

全文:

受限制的访问

作者简介

Vadim M. Minnigaliev

Bashkir State Medical University

编辑信件的主要联系方式.
Email: doctr@autorambler.ru
ORCID iD: 0009-0009-5890-8189

MD

俄罗斯联邦, 3 Lenin st., Ufa, 450008, Republic of Bashkortostan

Nuriya A. Khamadullina

Bashkir State Medical University

Email: nuriyakham@gmail.com
ORCID iD: 0009-0006-1533-9252
俄罗斯联邦, 3 Lenin st., Ufa, 450008, Republic of Bashkortostan

Mariya I. Gonchar

Bashkir State Medical University

Email: gonchar.maria@inbox.ru
ORCID iD: 0009-0006-9015-3693

MD

俄罗斯联邦, 3 Lenin st., Ufa, 450008, Republic of Bashkortostan

Dayana K. Ekhtanigova

H.M. Berbekov Kabardino-Balkarian State University

Email: ekhtanigova.dayana@mail.ru
ORCID iD: 0000-0003-0448-5079
俄罗斯联邦, Nalchik

Fatimat M. Sozaeva

H.M. Berbekov Kabardino-Balkarian State University

Email: fatima.sozaeva0207@yandex.ru
ORCID iD: 0000-0002-2201-3326
俄罗斯联邦, Nalchik

Asiyat M. Shirukova

H.M. Berbekov Kabardino-Balkarian State University

Email: shirukovaa@bk.ru
ORCID iD: 0009-0004-6045-3906
俄罗斯联邦, Nalchik

Haya Alhajali

H.M. Berbekov Kabardino-Balkarian State University

Email: haya.gobokai@gmail.com
ORCID iD: 0009-0004-1881-0359
俄罗斯联邦, Nalchik

Zalina M. Cherkesova

H.M. Berbekov Kabardino-Balkarian State University

Email: silenacherkesova@gmail.com
ORCID iD: 0009-0000-8598-2012
俄罗斯联邦, Nalchik

Laura M. Karakizova

H.M. Berbekov Kabardino-Balkarian State University

Email: karakizova.laura@bk.ru
ORCID iD: 0009-0006-0403-0743
俄罗斯联邦, Nalchik

Umraygan A. Ibragimova

Rostov State Medical University

Email: u.ibragimova.05@mail.ru
ORCID iD: 0009-0007-7069-5054
俄罗斯联邦, Rostov-оn-Don

Madina Z. Kerimova

Rostov State Medical University

Email: madina.kerimova2002@mail.ru
ORCID iD: 0009-0006-7190-9440
俄罗斯联邦, Rostov-оn-Don

参考

  1. Primary open-angle glaucoma. Clinical recommendations. Ministry of Health of the Russian Federation. 2020. 62 p.
  2. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12): e1221–e1234. doi: 10.1016/S2214–109X(17)30393–5
  3. Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12(11): e11686. doi: 10.7759/cureus.11686
  4. Movsisyan AB, Kuroedov AV, Arkharov MA, et al. Epidemiological analysis primary open-angle glaucoma incidence and prevalence in Russia. Russian Journal of Clinical Ophthalmology. 2022;22(1):3–10. EDN: VIMPIU doi: 10.32364/2311–7729–2022–22–1–3–10
  5. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review // JAMA. 2014;311(18):1901–1911. doi: 10.1001/jama.2014.3192
  6. Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision. 2023;7(3):54. doi: 10.3390/vision7030054
  7. Gambini G, Carlà MM, Giannuzzi F, et al. PreserFlo® MicroShunt: an overview of this minimally invasive device for open-angle glaucoma. Vision. 2022;6(1):12. doi: 10.3390/vision6010012
  8. Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater. 2017;105(1):211–221. doi: 10.1002/jbm.b.33558
  9. Saeed E, Gołaszewska K, Dmuchowska DA, et al. The PreserFlo microshunt in the context of minimally invasive glaucoma surgery: a narrative review. Int J Environ Res Public Health. 2023;20(4):2904. doi: 10.3390/ijerph20042904
  10. Sadruddin O, Pinchuk L, Angeles R, Palmberg P. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: A review. Eye Vis. 2019;6:36. doi: 10.1186/s40662-019-0162-1
  11. Baker ND, Barnebey HS, Moster MR, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710–1721. doi: 10.1016/j.ophtha.2021.05.023
  12. Panarelli JF, Moster MR, Garcia-Feijoo J, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: two-year results from a randomized, multicenter study. Ophthalmology. 2024;131(3):266–276. doi: 10.1016/j.ophtha.2023.09.023
  13. Mansouri K, Shaarawy T. Update on Schlemm’s canal based procedures. Middle East African Journal of Ophthalmology. 2015;22(1):38–44. doi: 10.4103/0974–9233.148347
  14. Ahmed IIK, Rhee DJ, Jones J, et al. Three-year findings of the HORIZON Trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. Ophthalmology. 2021;128(6):857–865. doi: 10.1016/j.ophtha.2020.11.004
  15. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126(1):29–37. doi: 10.1016/j.ophtha.2018.05.012
  16. De Francesco T, Ahmed IIK. Surgical augmentation of the suprachoroidal space: a novel material and implant. Clin Ophthalmol. 2023:2483–2492. doi: 10.2147/OPTH.S409958
  17. Grierson I, Minckler D, Rippy MK, et al. A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration. BMC Biomed Eng. 2020;2:1–10. doi: 10.1186/s42490-020-00045-1
  18. Denis P, Hirneiß C, Reddy KP, et al. A first-in-human study of the efficacy and safety of MINIject in patients with medically uncontrolled open-angle glaucoma (STAR-I). Ophthalmol Glaucoma. 2019;2(5):290–297. doi: 10.1016/j.ogla.2019.06.001
  19. Denis P, Hirneiß C, Durr GM, et al. Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial. Br J Ophthalmol. 2022;106(1):65–70. doi: 10.1136/bjophthalmol-2020-316888
  20. Shalaby WS, Lam SS, Arbabi A, et al. iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma. Indian J Ophthalmol. 2021;69(9):2488–2495. doi: 10.4103/ijo.IJO_308_21
  21. Samuelson TW, Sarkisian SRJr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811–821. doi: 10.1016/j.ophtha.2019.03.006
  22. Ahmed IIK, Podbielski DW, Patel V, et al. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3(2):103–113. doi: 10.1016/j.ogla.2019.11.009
  23. Fea AM, Cattel F, Gandolfi S, et al. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle glaucoma in Italy. BMC Health Serv Res. 2021;21:1–12. doi: 10.1186/s12913-021-06862-x
  24. Lima FE, Geraissate JC, Ávila M.P. A multicenter prospective comparative study evaluating cataract surgery and endoscopic cyclophotocoagulation either with or without iStent Inject implantation in Brazilian patients with glaucoma. Int Ophthalmol. 2023;43(5): 1665–1676. doi: 10.1007/s10792-022-02563-4
  25. Guo CY, Qi XH, Qi JM. Systematic review and meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy. Int J Ophthalmol. 2020;13(2):317. doi: 10.18240/ijo.2020.02.17
  26. Faria BM, Costa VP, Melillo GH, et al. Gonioscopy-assisted transluminal trabeculotomy for glaucoma: 1-year outcomes and success predictors. J Glaucoma. 2022;31(6):443–448. doi: 10.1097/IJG.0000000000002025
  27. Bozkurt E, Yenihayat F, Olgun A, et al. The efficacy of gonioscopy-assisted transluminal trabeculectomy combined with phacoemulsification. Int Ophthalmol. 2021;41:35–43. doi: 10.1007/s10792-020-01550-x
  28. Fontana L, De Maria M, Iannetta D, Moramarco A. Gonioscopy-assisted transluminal trabeculotomy for chronic angle-closure glaucoma: preliminary results. Graefes Arch Clin Exp Ophthalmol. 2021;260(2):3019–3026. doi: 10.1007/s00417-020-05400-z
  29. Sharkawi E, Artes PH, Lindegger DJ, et al. Gonioscopy-assisted transluminal trabeculotomy in primary angle-closure glaucoma. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):3019–3026. doi: 10.1007/s00417–021–05244–7
  30. Olgun A, Aktas Z, Ucgul AY. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma. Int Ophthalmol. 2020;40(5):1085–1093. doi: 10.1007/s10792-019-01271-w
  31. Hamze H, Mohite AA, Pandey P, et al. Comparison of 1-year surgical outcomes of combined cataract surgery and gonioscopy-assisted transluminal trabeculotomy (GATT) versus cataract surgery and iStent Inject. Graefes Arch Clin Exp Ophthalmol. 2021;259(10): 3035–3044. doi: 10.1007/s00417-021-05133-z
  32. Wang Y, Zhang W, Xin C, et al. Gonioscopy-assisted transluminal trabeculotomy for open-angle glaucoma with failed incisional glaucoma surgery: two-year results. BMC Ophthalmol. 2023;23(1):89. doi: 10.1186/s12886-023-02830-7
  33. Fea AM, Durr GM, Marolo P, et al. XEN® gel stent: a comprehensive review on its use as a treatment option for refractory glaucoma. Clin Ophthalmol. 2020;14:1805–1832. doi: 10.2147/OPTH.S178348
  34. Sheybani A, Vera V, Grover DS, et al. Gel stent versus trabeculectomy: the randomized, multicenter, gold-standard pathway study (GPS) of effectiveness and safety at 12 months. Am J Ophthalmol. 2023;252:306–325. doi: 10.1016/j.ajo.2023.03.026
  35. Fea AM, Bron AM, Economou MA, et al. European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg. 2020;46(3):441–450. doi: 10.1097/j.jcrs.0000000000000065
  36. Chan L, Moster MR, Bicket AK, et al. New devices in glaucoma. Ophthalmol Ther. 2023;12(5):2381–2395. doi: 10.1007/s40123-023-00780-3
  37. Geffen N, Kumar DA, Barayev E, et al. minimally invasive micro sclerostomy (MIMS) procedure: a novel glaucoma filtration procedure. J Glaucoma. 2022;31(3):191–200. doi: 10.1097/IJG.0000000000001955

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Search algorithm for studies

下载 (228KB)
索引源数据
3. Fig. 2. Illustration depicting the coronal cross-section of the anterior segment of the eye, highlighting the anatomic localization of each minimally invasive glaucoma surgery device category, including subconjunctival shunts, suprachoroidal outflow, as well as Schlemm’s canal targeted and trabecular outflow targeted devices. ABiC, ab interno canaloplasty; GATT, gonioscopy-assisted transluminal trabeculotomy; HDFS, high-frequency deep sclerotomy. Adapted from M. Balas and D.J. Matthew [6]

下载 (214KB)
索引源数据

版权所有 © Eco-Vector, 2024


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.